The phase 3 trial of more than 500 U.S. patients with chronic lymphocytic leukemia (CLL) found that a combination of rituximab and ibrutinib extended patient survival.
from WebMD Health https://www.webmd.com/cancer/news/20190731/drug-duo-may-be-a-weapon-against-a-common-leukemia?src=RSS_PUBLIC
0 Comments:
Post a Comment